Yttrium-90
Phase 1Radiopharmaceutical
Yttrium-90 is one of 71 small molecule programs targeting Liver Cancer. It is currently in Phase 1.
2
Indications
4
Total Trials
2
Active Trials
70
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
60 competitors in Liver Cancer
#DrugCompanyPhaseTrials
1Blenoxane
Bristol-Myers SquibbApproved
Taxol
TevaApproved
Idamycin
PfizerApproved
Opdivo
Bristol-Myers SquibbPhase 3
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Eloxatin
TevaPhase 3
Lenvima
EisaiPhase 3
Rapamune
PPrism Pharmaceuticals
Approved
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Bicnu
MMelissa K Accordino
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Liver Cancer2 trials
Hepatocellular Carcinoma1 trial
Liver1 trial
A Phase 1 Study of Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.
Active, not recruiting·UUniversity of Michigan Rogel Cancer Center·Preclinical·NCT04518748·70 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Yttrium-90. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details